Immune checkpoint inhibitor toxicity (irAE)
Immunotherapy complication · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Checkpoint inhibitors (e.g. -mab immunotherapies) can trigger autoimmune inflammation of any organ - colitis, pneumonitis, hepatitis, myocarditis, hypophysitis and adrenal failure - sometimes weeks after treatment. Recognition and early corticosteroids are key, with hormone replacement for endocrine effects.
Assessment
Investigations
- Identify recent/ongoing checkpoint-inhibitor therapy
- Organ-specific work-up (LFTs, troponin/ECG, cortisol, CXR, stool studies)
- Exclude infection
Management
- Recognise the immune-related adverse event and grade severity
- High-dose corticosteroids for moderate-severe organ toxicity
- Hormone replacement for hypophysitis/adrenal insufficiency (steroid +/- thyroid)
- Urgent treatment of myocarditis (high mortality)
- Oncology involvement; hold the immunotherapy
Drugs & doses
Methylprednisolone / prednisolone
Hydrocortisone (if adrenal/hypophysitis)
Disposition
Oncology/medical admission.
Any new organ dysfunction in a patient on immunotherapy is an immune-related adverse event until proven otherwise - steroids early, and never miss myocarditis or adrenal crisis.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.